Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by scarlet1967on Jun 15, 2021 1:56pm
85 Views
Post# 33389365

RE:RE:RE:RE:RE:RE:How should this be graded in the weekly report card?

RE:RE:RE:RE:RE:RE:How should this be graded in the weekly report card?I believe this might explain that language.
"Tumour chemoresistance:

As the chemotherapeutic agent flows out of cells using transporters such as various proteins resulting in less concentration of anticancer agent in the cancer cells thus less therapeutic effects!! however the targeted drug delivery escapes the chemoresistance as they don’t activated those transporters therefore the intracellular concentration of the drug is higher compared to standalone chemotherapeutic agent. As a result the multi drug resistance in traditional chemotherapy is mitigated by the targeted drug delivery technology."



qwerty22 wrote:

Some language looks a bit off. E.g. on SORT1 page preclinical studies would be better than preclinical trials, also this sentence doesn't doesn't make a lot of sense, esp the last part.

 "It was also observed in pre-clinical trials that our PDCs bypass a chemo efflux pump (multidrug resistance protein or MDR1), a known resistance mechanism, the resistance mechanism utilizing the endocytic pathway to carry the cytotoxic payload into the cancer cell."

Also I'm looking at it on an iPAD and I have to keep going back to navigate thru the menu to read each page which is pretty clunky and annoying. If I go to the SORT1 page there should be a quick navigation button to the next TH1902 page, and from TH1902 to TH1904 etc. The MENU  bar in general is clunky, feels like something from ten years ago, clicking thru four things to get to the page I want. Maybe it's just not great for iPAD.

There's other examples where the language/grammar is off. It needs a clean up.

Anyway progress.

 

scarlet1967 wrote: I give it a pass, definitely an improvement, each section has the relevant scientific studies, pipeline updated, looks much better maybe not as much as one wanted but overall better, still no partnership section! It will be good to update the IP and make some changes as mentioned earlier.
I don't think I would say this website is substandard compared to other companies websites anymore.

 

Often I have fantasies how they can bring more investors onboard then I realized their website was not even factual but no more complaints on that front anymore now keep on with the good work and make your messaging more frequent and sell the prospects of your business to the entire market. 

"

 

 

scarlet1967 wrote: I give it a pass, definitely an improvement, each section has the relevant scientific studies, pipeline updated, looks much better maybe not as much as one wanted but overall better, still no partnership section! It will be good to update the IP and make some changes as mentioned earlier.
I don't think I would say this website is substandard compared to other companies websites anymore.
Often I have fantasies how they can bring more investors onboard then I realized their website was not even factual but no more complaints on that front anymore now keep on with the good work and make your messaging more frequent and sell the prospects of your business to the entire market. 

 

 



<< Previous
Bullboard Posts
Next >>